Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Gene Ther. 2008 Mar 20;15(14):1024–1034. doi: 10.1038/gt.2008.30

Figure 6.

Figure 6

(a) Immunoprecipitation assay for active RhoA and immunoblotting for total RhoA, showed decrease in RhoA activity starting at 6 h following geldanamycin (GA) treatment, which was more prominent in combination-treated cells. (b) Transduction of MDA-MB-231 cells with the PHR-NegRhoA lentiviral vector expressing a dominant-negative RhoA (MOI 10), completely eliminated RhoA-activity and significantly increased measles-induced fusion (c) and syncytial area (d) following measles virus infection. Lentiviral vectors expressing a constitutively active RhoA (PHR-ActRhoA) or GFP (PHR-GFP) were employed as controls. Asterisk (*) denotes statistical significance.